Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 1
2013 1
2014 1
2015 2
2017 2
2018 2
2019 2
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes.
D'Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, Mata P, Sánchez-Hernández RM, Prieto-Matos P, Real JT, Ascaso JF, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M. D'Erasmo L, et al. J Am Coll Cardiol. 2018 Jan 23;71(3):279-288. doi: 10.1016/j.jacc.2017.11.028. J Am Coll Cardiol. 2018. PMID: 29348020 Free article.
BACKGROUND: Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data for clinical management and cardiovascular outcomes in AR …
BACKGROUND: Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosc …
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ESG, Robinson P, Lei L, Ray KK. Ballantyne CM, et al. Am J Cardiol. 2022 Jul 1;174:1-11. doi: 10.1016/j.amjcard.2022.03.020. Epub 2022 Apr 26. Am J Cardiol. 2022. PMID: 35483979 Free article. Clinical Trial.
Limited data exist on the long-term safety and efficacy of bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor, for lowering low-density lipoprotein cholesterol (LDL-C). ...
Limited data exist on the long-term safety and efficacy of bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor, …
Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D, Du N, Sulaica EM, Wanat MA. Nguyen D, et al. Ann Pharmacother. 2021 Feb;55(2):246-251. doi: 10.1177/1060028020941083. Epub 2020 Jul 16. Ann Pharmacother. 2021. PMID: 32674598 Review.
Bempedoic acid may be a reasonable adjunct for LDL-C reduction, though further evaluation of cardiovascular outcomes with bempedoic acid in this population is needed. CONCLUSIONS: The recent FDA approval of bempedoic acid offers an additional option for lowering LDL …
Bempedoic acid may be a reasonable adjunct for LDL-C reduction, though further evaluation of cardiovascular outcomes with bemp …
Pleiotropic effects of regular lipoprotein-apheresis.
Sinzinger H, Steiner S, Derfler K. Sinzinger H, et al. Atheroscler Suppl. 2017 Nov;30:122-127. doi: 10.1016/j.atherosclerosissup.2017.05.032. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096827
METHODS: Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of lipoproteins (DALI) or dextran sulfate (DS) were examined. ...DISCUSSION: These findings indicate that beyond the well known lipid/lipoprote …
METHODS: Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of …
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, Harats D, Ma PT, Le Maulf F, Melezínková H, Gold A, Sager P. Stein EA, et al. Am J Cardiol. 2007 Nov 1;100(9):1387-96. doi: 10.1016/j.amjcard.2007.06.029. Epub 2007 Aug 21. Am J Cardiol. 2007. PMID: 17950795 Clinical Trial.
The initial period had 2 primary end points: percentage of patients achieving National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III LDL cholesterol goals at 12 weeks, and long-term safety, assessed during 48 weeks by incidence and seve …
The initial period had 2 primary end points: percentage of patients achieving National Cholesterol Education Program (NCEP) Adult Treatment …
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D. Avellone G, et al. Int Angiol. 2010 Dec;29(6):514-24. Int Angiol. 2010. PMID: 21173733 Clinical Trial.
Ezetimibe, a novel compound, selectively inhibits cholesterol uptake and when associated with statins has an additional low-density lipoprotein cholesterol (LDL-C) reducing effect. The aim of this study is to evaluate the effects of long-term combined Ezetimibe/Simv …
Ezetimibe, a novel compound, selectively inhibits cholesterol uptake and when associated with statins has an additional low-density lipoprot …
Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
Gelsinger C, Steinhagen-Thiessen E, Kassner U. Gelsinger C, et al. Drugs. 2012 Jul 30;72(11):1445-55. doi: 10.2165/11635060-000000000-00000. Drugs. 2012. PMID: 22799743
Although the short-term efficacy and safety of mipomersen have been proven, side effects like injection-site reactions (up to 90-100%), increased liver enzymes, cephalgias, nasopharyngitis, myalgia, nausea and fatigue must be mentioned and critically discussed. Furthermore, we ne …
Although the short-term efficacy and safety of mipomersen have been proven, side effects like injection-site reactions (up to 90-100%), incr …
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Santos RD, et al. Eur Heart J. 2015 Mar 1;36(9):566-75. doi: 10.1093/eurheartj/eht549. Epub 2013 Dec 23. Eur Heart J. 2015. PMID: 24366918 Free PMC article. Clinical Trial.
Mean high-density lipoprotein cholesterol increased from baseline by 7 and 6% at weeks 26 and 52, respectively. The long-term safety profile of mipomersen was similar to that reported in the associated randomized placebo-controlled Phase 3 trials. ...The median alan …
Mean high-density lipoprotein cholesterol increased from baseline by 7 and 6% at weeks 26 and 52, respectively. The long-term
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. McCullough PA, et al. Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040. Epub 2018 Feb 2. Am J Cardiol. 2018. PMID: 29472008 Free article.
Patients with previous atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) are at high risk of future cardiovascular events. ...Patients with (n = 2,449) and without (n = 1,050) ASCVD were pooled from the FH …
Patients with previous atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) …
14 results